RFL Earnings — Rafael Holdings, Inc. Class B Common Stock Post-ER Performance | BigEarnings
RFL — Rafael Holdings, Inc. Class B Common Stock
XNYS · Real Estate · Real Estate Services
Price$1.31
Market Cap$67.2M
P/E—
52W Range$1.12 – $3.19
Next Earnings2026-06-15
About Rafael Holdings, Inc. Class B Common Stock
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
